Paul Stoffels, Galapagos CEO (Michael Kovac/Getty Images)

'For­ward, faster' and 200 jobs lighter as fi­bro­sis and kid­ney dis­ease get cut, Gala­pa­gos CEO Stof­fels once again spot­lights deals

New Gala­pa­gos CEO Paul Stof­fels — best known for his turn as the long­time CSO at J&J — has come up with a three-pronged strat­e­gy to dig a way out of the big hole the biotech finds it­self in. And it calls for tak­ing out the bud­get axe and giv­ing the staff 200 whacks so they can put more mon­ey in­to deals.

“Our new fit-for-pur­pose or­ga­ni­za­tion­al struc­ture and op­er­at­ing mod­el will fo­cus on ac­cel­er­at­ing our pipeline in im­munol­o­gy and on­col­o­gy, sup­port­ed by ex­ter­nal­ly sourced op­por­tu­ni­ties, and we will dis­con­tin­ue our ac­tiv­i­ties in fi­bro­sis and kid­ney dis­ease,” Stof­fels not­ed in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.